3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
3
Fallopian Tube Neoplasms
3
Uterine Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Muscle Invasive Bladder Cancer
1
Meningeal Carcinomatosis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Brenner Tumor
1
Interventions
vistusertib
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Muscle Invasive Bladder Cancer
×
adavosertib
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled